In-Licensing:
- Our business model is referred to as “In-Licensing”
- NanoDev acquires patented cancer therapeutic intellectual property that is still in pre-clinical or clinical development. We license products that are fairly well advanced in pre-clinical development and then focus is on clinical phase progression. Our method eliminates the early development costs, reduces risk and adds value to NanoDev.
- Our founding members include research doctors with medical and clinical
development expertise allowing NanoDev to carry out clinical trials at a much lower cost, expediting development.
The Problem:
- Research Institutions will patent discoveries but will typically not invest in their commercialization.
- Institutions with departments dedicated to commercialization, typically just license Intellectual Property (IP). Commercialization is left to the entity that has acquired the license.
- Commercialization results from advancing IP through clinical trials. The issue here is that this process can cost as much as $250 million US.
- Another issue is that after investment, there are no guarantees of success. Only 12%-15% of therapeutic intellectual property completes all clinical trials and results in a return on investment (ROI) or profit.
- There must be a better way …
The NanoDev Solution:
- NanoDev provides resources for commercialization activity, dedicating investment and resources to IND and clinical trials.
- We multiply effort and cut costs.
- Our focused effort allows us to license and develop multiple products.
- Collaboration by member partners expedites effort.
- Access to global institutional resources reduces cost.
- NanoDev investors have an increased chance for Return On Investment (ROI).
- Developing multiple IP programs at the same time, increases success rate.
- Member partner expertise working as a team, will expedite results.
- NanoDev licenses IP after patent approvals saving upfront costs.